Agios Pharmaceuticals (NASDAQ:AGIO) had its price target dropped by equities research analysts at Piper Jaffray Companies to $100.00 in a note issued to investors on Thursday, The Fly reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective suggests a potential upside of 74.16% from the stock’s current price.

AGIO has been the topic of several other research reports. BidaskClub lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Oppenheimer reiterated a “hold” rating on shares of Agios Pharmaceuticals in a report on Thursday, November 1st. ValuEngine lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 25th. reiterated a “hold” rating on shares of Agios Pharmaceuticals in a report on Friday, November 16th. Finally, Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $97.00.

Shares of NASDAQ AGIO traded up $3.39 during trading on Thursday, reaching $57.42. The company had a trading volume of 862,234 shares, compared to its average volume of 502,729. Agios Pharmaceuticals has a 12 month low of $41.63 and a 12 month high of $99.82. The firm has a market capitalization of $3.22 billion, a PE ratio of -8.51 and a beta of 2.38.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.07. Agios Pharmaceuticals had a negative return on equity of 48.51% and a negative net margin of 461.78%. The firm had revenue of $30.00 million for the quarter, compared to analyst estimates of $19.98 million. During the same quarter in the previous year, the company posted ($1.81) EPS. The business’s revenue was up 200.0% on a year-over-year basis. On average, analysts forecast that Agios Pharmaceuticals will post -6.12 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the business. FMR LLC raised its stake in shares of Agios Pharmaceuticals by 0.7% in the third quarter. FMR LLC now owns 8,698,886 shares of the biopharmaceutical company’s stock worth $670,858,000 after purchasing an additional 58,043 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Agios Pharmaceuticals by 2.7% in the third quarter. Vanguard Group Inc. now owns 4,251,439 shares of the biopharmaceutical company’s stock worth $327,871,000 after purchasing an additional 109,849 shares during the last quarter. Vanguard Group Inc raised its stake in shares of Agios Pharmaceuticals by 2.7% in the third quarter. Vanguard Group Inc now owns 4,251,439 shares of the biopharmaceutical company’s stock worth $327,871,000 after purchasing an additional 109,849 shares during the last quarter. BlackRock Inc. raised its stake in shares of Agios Pharmaceuticals by 1.2% in the fourth quarter. BlackRock Inc. now owns 3,324,479 shares of the biopharmaceutical company’s stock worth $153,292,000 after purchasing an additional 38,637 shares during the last quarter. Finally, Capital International Investors raised its stake in shares of Agios Pharmaceuticals by 10.4% in the third quarter. Capital International Investors now owns 3,096,422 shares of the biopharmaceutical company’s stock worth $238,796,000 after purchasing an additional 291,393 shares during the last quarter. Institutional investors and hedge funds own 95.40% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Article: Lock-Up Period Expiration

The Fly

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.